Local Control of Brain Metastases with Osimertinib Alone in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

被引：0

作者：

Hui, C. ^{[1
]}

Qu, V. ^{[2
]}

Wang, J. Y. ^{[2
]}

Von Eyben, R. ^{[3
]}

Chang, Y. C. ^{[4
]}

Chiang, P. L. ^{[4
]}

Liang, C. H. ^{[4
]}

Lin, J. Y. ^{[4
]}

Lu, J. T. ^{[4
]}

Li, G. ^{[5
]}

Hayden, M. ^{[5
]}

Myall, N. ^{[6
]}

Soltys, S. G. ^{[7
]}

Pollom, E. ^{[3
]}

机构：

[1] Stanford Univ, Palo Alto, CA 94304 USA

[2] Stanford Univ, Sch Med, Dept Radiat Oncol, Palo Alto, CA 94304 USA

[3] Stanford Univ, Dept Radiat Oncol, Sch Med, Stanford, CA 94305 USA

[4] Vysioneer Inc, Cambridge, MA USA

[5] Stanford Canc Inst, Dept Neurosurg, Stanford, CA USA

[6] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA

[7] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2022年 / 114卷 / 03期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2120

引用

页码：E54 / E55

页数：2

共 50 条

[31] Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer
Rosell, Rafael
Gonzalez-Cao, Maria
Codony-Servat, Jordi
Molina-Vila, Miguel Angel
Mayo de las Casas, Clara
Ito, Masaoki
TRANSLATIONAL CANCER RESEARCH, 2023, 12 (03) : 456 - 460
[32] Phase I/II trial of dasatinib and osimertinib in patients with advanced EGFR-mutant non-small cell lung cancer
Kim, Chul
Liu, Stephen V.
Subramaniam, Deepa Suresh
Giaccone, Giuseppe
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[33] Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer
Lemmon, Christopher A.
Zabor, Emily C.
Pennell, Nathan A.
ONCOLOGIST, 2022, 27 (05): : 407 - 413
[34] Three Treatments for EGFR-Mutant Non-Small-Cell Lung Cancer with Brain Metastases
Fan, Y.
Yu, X.
Wang, H.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2228 - S2228
[35] Radiation As a Local Ablative Therapy Option for Oligoprogressive EGFR-Mutant Non-Small Cell Lung Cancer after Treatment with Osimertinib
Kesarwala, A. H.
Kim, C.
Jones, J. C.
Kaushal, A.
Roper, N.
Hoang, C. D.
Szabo, E.
Connolly, M.
Padiernos, E.
Cultraro, C.
Waris, M.
Gao, S.
Steinberg, S. M.
Khan, J.
Rajan, A.
Guha, U.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 99 (02): : E467 - E468
[36] Clinical Value and Optimal Timing of Cranial Local Therapy among EGFR-Mutant Non-small-cell Lung Cancer with Brain Metastases in the Era of Osimertinib
Yu, F.
Ni, J.
Yu, W.
Fu, X.
Zhu, Z.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (03): : S175 - S175
[37] Treatment outcomes of EGFR-TKI with or without locoregional brain therapy in advanced EGFR-mutant non-small cell lung cancer patients with brain metastases
Linh, Do Mai
Thinh, Tran Huy
Hieu, Nguyen-Van
Duc, Nguyen Minh
WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY, 2023, 27 (02): : 71 - 79
[38] Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada
Ezeife, Doreen A.
Kirk, Veronica
Chew, Derek S.
Nixon, Nancy A.
Lee, Roy
Le, Lisa W.
Chan, Kelvin K. -W.
Leighl, Natasha B.
LUNG CANCER, 2018, 125 : 1 - 7
[39] An exploration of the clinical progression models of osimertinib in the treatment of advanced EGFR-mutant non-small cell lung cancer
Shi, Yue
Jiang, Yingying
Pan, Banzhou
Wang, Zihan
Li, Hang
Ma, Yuxin
Liu, Yilin
He, Kang
Wang, Zhitong
Lu, Jianwei
Shi, Meiqi
Shen, Bo
Zhou, Guoren
Yin, Rong
Rossi, Antonio
Ito, Kentaro
Santarpia, Mariacarmela
Um, Sang-Won
Wang, Xiaohua
Chen, Cheng
Feng, Jifeng
TRANSLATIONAL LUNG CANCER RESEARCH, 2022, : 817 - 831
[40] Neurological death in patients with EGFR-mutant non-small cell lung cancer.
Ramotar, Matthew
Barnes, Sierra
Doherty, Mark
Shultz, David Benjamin
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →